Supportive effect of carnitine on hepatitis C virus eradication therapy
Not Applicable
- Conditions
- Chronic hepatitis type C, cirrhosis type C
- Registration Number
- JPRN-UMIN000026079
- Lead Sponsor
- Third department of Internal Medicine, Nara Medical University
- Brief Summary
A significantly smaller decrease in hemoglobin concentration was observed in group B (treated with sofosbuvir, ribavirin, and L-carnitine) compared to group A (treated with sofosbuvir plus ribavirin for 3 months) at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with oral intake difficulty 2)Patients with severe digestive disease 3)Pregnant woman, lactating woman, or a woman suspected of pregnancy 4)Patients with severe allergic reaction 5)Patients with drug abuse or psycological disorders 6)Carnitine >=92mmol/
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method